Hong Kong will become the first city in Asia to conduct clinical trials of a non-invasive treatment for kidney tumours, with tycoon Li Ka-shing funding places for 30 patients across three private hospitals. The Li Ka Shing Foundation announced on Wednesday that CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would launch the trials using histotripsy, a technology that uses focused sound waves to break apart tumours without surgical incisions. The trials...
Health
Li Ka-shing funds Asia’s first non-invasive kidney tumour trials in Hong Kong
South China Morning Post
The Perspectives
0 verified voices · Three viewpoints · Real discourse
Only verified Neural Identity holders can participate in The Perspectives.
Sign In with Neural Identity
Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective
